Metallothioneins and resistance to cisplatin and radiation in prostate cancer

Urology

Volumn 67, Issue 6, 2006, Pages 1341-1347

  Smith, David J ^a   Jaggi, Meena ^a   Zhang, Wenguang ^a   Galich, Anton ^a   Du, Cheng ^a   Sterrett, Samuel P ^a   Smith, Lynette M ^b   Balaji, K C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METALLOTHIONEIN; ZINC; ZINC SULFATE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL STRAIN LNCAP; CELL VIABILITY; CLONOGENIC ASSAY; DATA ANALYSIS; DNA MICROARRAY; DOSE RESPONSE; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; STATISTICAL SIGNIFICANCE; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; METALLOTHIONEIN; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TUMOR CELLS, CULTURED; ZINC;

EID: 33744550703     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.12.032     Document Type: Article

References (17)

1. Costello L.C., and Franklin R.B. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 35 (1998) 285-296
2. Ebadi M., and Iversen P.L. Metallothionein in carcinogenesis and cancer chemotherapy. Gen Pharmacol 25 (1994) 1297-1310
3. Theocharis S.E., Margeli A.P., and Koutselinis A. Metallothionein. a multifunctional protein from toxicity to cancer. Int J Biol Markers 18 (2003) 162-169
4. Wang G., Reed E., and Li Q.Q. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 12 (2004) 955-965
5. Theocharis S.E., Margeli A.P., Klijanienko J.T., et al. Metallothionein expression in human neoplasia. Histopathology 45 (2004) 103-118
6. Garrett S.H., Sens M.A., Shukla D., et al. Metallothionein isoform 1 and 2 gene expression in the human prostate. downregulation of MT-1X in advanced prostate cancer. Prostate 43 (2000) 125-135
7. Jaggi M., Rao P., Smith D., et al. E-cadherin phosphorylation by PKD1/PKC mu is associated with altered cellular aggregation and motility in prostate cancer. Cancer Res 65 (2005) 483-492
8. Telford W.G., King L.E., and Fraker P.J. Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif 24 (1991) 447-459
9. Mocchegiani E., Bertoni-Freddari C., Marcellini F., et al. Brain, aging and neurodegeneration. role of zinc ion availability. Prog Neurobiol 75 (2005) 367-390
10. Cai L., Satoh M., Tohyama C., et al. Metallothionein in radiation exposure. its induction and protective role. Toxicology 132 (1999) 85-98
11. Kondo Y., Yamagata K., Satoh M., et al. Optimal administration schedule of cisplatin for bladder tumor with minimal induction of metallothionein. J Urol 170 (2003) 2467-2470
12. Kondo Y., Kuo S.M., Watkins S.C., et al. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 55 (1995) 474-477
13. Metcalfe S.A., Cain K., and Hill B.T. Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett 31 (1986) 163-169
14. Saga Y., Hashimoto H., Yachiku S., et al. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors. Int J Urol 11 (2004) 407-415
15. Pisansky T.M. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer. Urology 62 suppl 1 (2003) 36-45
16. Strohl R.A. External beam radiation therapy in gynecologic cancers. NAACOGS Clin Issu Perinat Womens Health Nurs 1 (1990) 525-531
17. Rao P.S., Jaggi M., Smith D.J., et al. Metallothionein 2A interacts with the kinase domain of PKCmu in prostate cancer. Biochem Biophys Res Commun 310 (2003) 1032-1038